Pharmatimes.com Website Review

The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future How CSOs can look to the future to forge successful relationships with pharma Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending Researchers at Imperial and Bayer Pharmaceuticals are partnering up to explore how artificial intelligence (AI) can be used to accelerate the Scientists at the University of Birmingham have announced the discovery of a protein that could hold the key to novel gene therapies A practice-changing new clinical trial has been found to reduce long-term radiotherapy side effects in women with breast cancer. Gilead Sciences and Agenus have announced a partnership to focus on the development and commercialisation of up to five novel Excitement around the transformative potential of AI and machine learning continues to build. Companies will need to adapt their individual offers to draw in AI specialists, but as an industry UK pharma should also continue to champion itself and the unique career advantages it holds for the best and brightest researchers. Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government's second sector deal for the life sciences industry. Mark Toms, chief scientific officer at Novartis Pharmaceuticals UK, looks at how to address the challenges of recruiting for Alzheimer’s There are around 7,000 rare diseases for which there currently exists no authorised or satisfactory method of treatment, highlighting a vast area of unmet need, and yet the clinical development of orphan drugs is still fraught with many practical challenges. The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future